ClinicalTrials.gg
TerminatedNCT06447506AtDvanceUpdated Jun 16, 2026Results posted

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

A Phase 2 interventional study of GSK1070806 and Placebo in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Terminated at 51 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.

Enrollment
8th of 18
79 · median 42
Started
2024
the only one that year
Phase 2
8 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, and was the 19th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Dermatitis, Atopic by GlaxoSmithKline as a file.
02

Study summary

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Atopic dermatits
  • Dermatitis
  • Eczema
  • GSK1070806
  • Safety
  • Efficacy
  • Immune system Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must sign and date the consent document.
  • Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who have completed the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806.
  • Be intentional and able to visit the doctor at the clinic by appointment and follow all procedures related to research studies and questionnaires (able to read and understand Patient-reported outcomes (PRO) questionnaires and be able to use electronic devices).
  • The use of methods for females should be consistent with local regulations on contraceptive methods of participants participating in clinical research programs.
  • Female participants are eligible to participate in the research program if they are not pregnant or breastfeeding and meet one of the following conditions:
  • It is Woman of nonchildbearing potential (WONCBP).
  • It is Woman of (WOCBP) and uses a highly effective contraceptive method that has a failure rate less than (\<) 1 percent (%) during the trial dose period and for at least 16 weeks after the last dose of the research drug. We should assess the likelihood of contraceptive failure (e.g., non-cooperation, early contraception) associated with the first dose of the drug.
  • WOCBP must obtain a negative result in a highly sensitive pregnancy test (by urine or serum test, as prescribed by local regulations) before receiving the first dose of the research drug.
  • If the urine test is positive, or the negative result cannot be confirmed (i.e., the result is unclear), a pregnancy test by serum test is required. In such cases, If the serum is tested, the test result is positive. Participants must be excluded from the research project.
  • Additional requirements for testing pregnancy during and after exposure to the drug.
  • The researcher is responsible for examining medical history, menstrual cycle history, and sexual activity in the near term. To reduce the risk of screening pregnant women who may not be detected at the beginning of pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Permanent discontinuation of the study drug at any time during GSK's qualifying Phase 2 AtD (NCT05999799) or a medical condition that would hinder GSK's participation in the Phase 2 219538 (NCT05999799) AtD research project.
  • Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD research project, developed adverse event (AE) or Serious adverse event (SAE) based on laboratory parameters, physical examination, vital signs, (ECG), medical history, etc. Medical history, in the opinion of the researchers, suggests that if medicinal product (IMP) is continued, it may cause unnecessary risk to the participants.
  • Topical medications for AtD within 1 week prior to your appointment at Day 1, such as: Topical calcineurin inhibitors (TCI)/ Topical (TCS), Phosphodiesterase-4 (PDE-4) and Janus activation kinase inhibitors (JAKi) for external use.
  • Topical corticosteroids (TCS) (such as hydrocortisone, betamethasone)
  • Topical calcineurin inhibitors (TCI) (such as tacrolimus, pimecrolimus)
  • Phosphodiesterase-4 (PDE4) inhibitor for external use (e.g., crisaborole)
  • JAKi for external use (e.g. ruxolitinib)
  • Medications for topical use, or other herbal/traditional medicines that may affect the AtD that the participants are in.
  • Participant who received systemic therapy, which is considered , including systemic therapy used as a rescue medication for AtD, from the screening for GSK's Phase 2 AtD 219538 research project until the LTE protocol began, were unable to participate in the research project.
  • Chronic uncontrolled diseases that may require immediate oral corticosteroids, such as severe uncontrolled asthma (defined as having an Asthma control questionnaire (ACQ)-5 score greater than or equal to (>=) of 1.5 or a history of asthma exacerbations. >= 2 times within the last 12 months, requiring systemic corticosteroid [oral and/or intravenous medication] or requiring a >-24-hour hospital stay)
  • Experience participating in previous/current clinical research projects.
  • The participants have participated in any other clinical research studies. This is in addition to GSK's Phase 2 219538 (NCT05999799) research project.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Placebo comparator
    Placebo/Placebo

    Participants were previously treated with placebo in parent Study 219538 (NCT05999799) and continued on placebo subcutaneous (SC) injection in this long-term extension (LTE) study.

    Drug: Placebo

  • Experimental
    Placebo/GSK1070806 Dose Level 4

    Participants were previously treated with placebo in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.

    Drug: GSK1070806 · Drug: Placebo

  • Experimental
    GSK1070806 Dose Level 1/GSK1070806 Dose Level 1

    Participants were previously treated with GSK1070806 dose level 1 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 1 SC injection in this LTE study. Dose level 1 is the lowest dose level.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 1/GSK1070806 Dose Level 4

    Participants were previously treated with GSK1070806 dose level 1 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 2/GSK1070806 Dose Level 2

    Participants were previously treated with GSK1070806 dose level 2 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 2 SC injection in this LTE study. Dose level 2 is greater than dose level 1.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 2/GSK1070806 Dose Level 4

    Participants were previously treated with GSK1070806 dose level 2 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 3/GSK1070806 Dose Level 3

    Participants were previously treated with GSK1070806 dose level 3 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 3 SC injection in this LTE study. Dose level 3 is greater than dose level 2.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 3/GSK1070806 Dose Level 4

    Participants were previously treated with GSK1070806 dose level 3 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 4/GSK1070806 Dose Level 4

    Participants were previously treated with GSK1070806 dose level 4 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.

    Drug: GSK1070806

Interventions

  • Participants will receive GSK1070806

  • DrugPlacebo

    Participants will receive Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Safety Analysis Set included all assigned participants who received at least 1 dose of study intervention in this LTE study. Participants were analyzed according to the intervention they actually received.

    Time frame: Up to Week 59

  2. Number of Participants With TEAEs Leading to Permanent Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Number of participants with TEAE leading to permanent discontinuation of GSK1070806 were reported.

    Time frame: Up to Week 59

  3. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), is a suspected transmission of any infectious agent via an authorized medicinal product, and medically important were categorized as SAE.

    Time frame: Up to Week 59

  4. Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI)

    AESI for GSK1070806 include serious infections, opportunistic infections, serious hypersensitivity reactions, and injection site reactions (ISRs). A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state.

    Time frame: Up to Week 59

Secondary outcomes

  1. Number of Participants Who Achieved Investigators Global Assessment (IGA) Response (IGA Score of 0 or 1 and a Reduction of Greater Than or Equal to [>=]2 Points From Baseline) at Weeks 16, 32, and 48

    IGA is a clinical tool to assess current state/severity of participant's atopic dermatitis (AtD). It is static 5-point morphological assessment of overall disease severity at time of assessment (TOA) determined by investigator, sub-investigator, or trained healthcare professional with required qualifications on scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, \& 4=severe). Higher score=high severity of disease. Data for IGA 0 or 1 responders is presented in this outcome measure. IGA 0 or 1 responders: participants whose IGA score was 'Clear' (0) or 'Almost Clear' (1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned Dose Level (DL) modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

    Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48

  2. Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in Eczema Area and Severity Index (EASI) Score From Baseline at Weeks 16, 32 and 48

    EASI scoring system is standardized clinical tool for assessment of extent(area) \& severity of AtD.Severity of clinical signs of AtD(erythema, induration/papulation,excoriation \& lichenification) scored separately for each of 4 body regions(head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

    Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32 and 48

  3. Number of Participants Who Achieved Reduction of >=4 Points in Peak Pruritus Numerical Rating Scale (PP-NRS) Score From Baseline at Weeks 16, 32, and 48

    PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Higher scores indicated worst itch. 2 participants had their assigned dose level (DL) modified during the study, hence were included in treatment arm of the highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Baseline was averaged from daily values from Day -7 to Day -1 of the parent study 219538 (NCT05999799).

    Time frame: Baseline (Day -7 to Day -1 from the parent study), Weeks 16, 32, and 48

  4. Number of Participants Who Maintained IGA Response (IGA Score of 0 or 1 and a Reduction of >=2 Points From Baseline) at Weeks 16, 32, and 48

    IGA is clinical tool to assess current state/severity of a participant's AtD. It measures overall disease severity at TOA(determined by investigator) using static 5-point scale(0-4): 0=clear,1=almost clear,2=mild,3=moderate,4-=severe. Higher scores indicate greater severity. IGA 0/1 responders are participants whose IGA score was 'Clear'(0) or 'Almost Clear'(1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.

    Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48

  5. Number of Participants Who Maintained Response of Reduction of >= 75% in EASI Score From Baseline at Weeks 16, 32, and 48

    EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. 2 participants had their assigned DL modified during study, hence included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.

    Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48

  6. Percent Change From Baseline (CFB) in EASI Score at Weeks 16, 32, and 48

    EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. CFB=post-dose visit value minus Baseline value (BV). Percent CFB=CFB value divided by BV \& multiplied by 100. Two participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

    Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48

07

Results

Posted Jun 16, 2026
Limitations and caveats
This study was terminated after the parent study 219538 (NCT05999799) met pre-defined futility criteria.

Participant flow

This is long-term extension (LTE) study of parent study 219538 (NCT05999799). A total of 79 participants were enrolled in this study. This study was terminated after the parent study 219538 (NCT05999799) met pre-defined futility criteria.

Participant flow — Overall Study
MilestonePlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Started313310951827
Participants with baseline peak pruritus numerical rating scale (pp-nrs) score >=4313211861822
Completed000000000
Not completed313310951827
Withdrew: Adverse event100000000
Withdrew: Lack of efficacy000000010
Withdrew: Withdrawal by subject031341107
Withdrew: Study terminated by sponsor21027540720

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Safety Analysis Set included all assigned participants who received at least 1 dose of study intervention in this LTE study. Participants were analyzed according to the intervention they actually received.

Time frame:
Up to Week 59
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Number of Participants With Treatment Emergent Adverse Events (TEAEs)11106341511
PrimaryNumber of Participants With TEAEs Leading to Permanent Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Number of participants with TEAE leading to permanent discontinuation of GSK1070806 were reported.

Time frame:
Up to Week 59
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Permanent Discontinuation
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Number of Participants With TEAEs Leading to Permanent Discontinuation100000000
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), is a suspected transmission of any infectious agent via an authorized medicinal product, and medically important were categorized as SAE.

Time frame:
Up to Week 59
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Number of Participants With Serious Adverse Events (SAEs)100100000
PrimaryNumber of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI)

AESI for GSK1070806 include serious infections, opportunistic infections, serious hypersensitivity reactions, and injection site reactions (ISRs). A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state.

Time frame:
Up to Week 59
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI)
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI)100100000
SecondaryNumber of Participants Who Achieved Investigators Global Assessment (IGA) Response (IGA Score of 0 or 1 and a Reduction of Greater Than or Equal to [>=]2 Points From Baseline) at Weeks 16, 32, and 48

IGA is a clinical tool to assess current state/severity of participant's atopic dermatitis (AtD). It is static 5-point morphological assessment of overall disease severity at time of assessment (TOA) determined by investigator, sub-investigator, or trained healthcare professional with required qualifications on scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, \& 4=severe). Higher score=high severity of disease. Data for IGA 0 or 1 responders is presented in this outcome measure. IGA 0 or 1 responders: participants whose IGA score was 'Clear' (0) or 'Almost Clear' (1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned Dose Level (DL) modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

Time frame:
Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Investigators Global Assessment (IGA) Response (IGA Score of 0 or 1 and a Reduction of Greater Than or Equal to [>=]2 Points From Baseline) at Weeks 16, 32, and 48
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16241141—19
Week 3213—142—02
Week 48—1—————00
SecondaryNumber of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in Eczema Area and Severity Index (EASI) Score From Baseline at Weeks 16, 32 and 48

EASI scoring system is standardized clinical tool for assessment of extent(area) \& severity of AtD.Severity of clinical signs of AtD(erythema, induration/papulation,excoriation \& lichenification) scored separately for each of 4 body regions(head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

Time frame:
Baseline (Day 1 from the parent study), Weeks 16, 32 and 48
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in Eczema Area and Severity Index (EASI) Score From Baseline at Weeks 16, 32 and 48
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16281152—212
Week 3215—342—06
Week 48—1—————10
SecondaryNumber of Participants Who Achieved Reduction of >=4 Points in Peak Pruritus Numerical Rating Scale (PP-NRS) Score From Baseline at Weeks 16, 32, and 48

PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Higher scores indicated worst itch. 2 participants had their assigned dose level (DL) modified during the study, hence were included in treatment arm of the highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Baseline was averaged from daily values from Day -7 to Day -1 of the parent study 219538 (NCT05999799).

Time frame:
Baseline (Day -7 to Day -1 from the parent study), Weeks 16, 32, and 48
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of >=4 Points in Peak Pruritus Numerical Rating Scale (PP-NRS) Score From Baseline at Weeks 16, 32, and 48
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16161202—23
Week 3205—131—02
Week 48—0—————00
SecondaryNumber of Participants Who Maintained IGA Response (IGA Score of 0 or 1 and a Reduction of >=2 Points From Baseline) at Weeks 16, 32, and 48

IGA is clinical tool to assess current state/severity of a participant's AtD. It measures overall disease severity at TOA(determined by investigator) using static 5-point scale(0-4): 0=clear,1=almost clear,2=mild,3=moderate,4-=severe. Higher scores indicate greater severity. IGA 0/1 responders are participants whose IGA score was 'Clear'(0) or 'Almost Clear'(1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.

Time frame:
Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Reported as:
Count of participants · Participants
Number of Participants Who Maintained IGA Response (IGA Score of 0 or 1 and a Reduction of >=2 Points From Baseline) at Weeks 16, 32, and 48
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16241141—19
Week 3212——31——1
SecondaryNumber of Participants Who Maintained Response of Reduction of >= 75% in EASI Score From Baseline at Weeks 16, 32, and 48

EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. 2 participants had their assigned DL modified during study, hence included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.

Time frame:
Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Reported as:
Count of participants · Participants
Number of Participants Who Maintained Response of Reduction of >= 75% in EASI Score From Baseline at Weeks 16, 32, and 48
ParticipantsPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16281152—212
Week 3214——42—05
Week 48—0——————0
SecondaryPercent Change From Baseline (CFB) in EASI Score at Weeks 16, 32, and 48

EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. CFB=post-dose visit value minus Baseline value (BV). Percent CFB=CFB value divided by BV \& multiplied by 100. Two participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.

Time frame:
Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Reported as:
Mean · Percent change
Percent Change From Baseline (CFB) in EASI Score at Weeks 16, 32, and 48
Percent changePlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Week 16-98.94 ± 1.498-80.32 ± 17.697-66.76 ± 47.012-32.79 ± 49.095-95.82 ± 3.520-65.75 ± 22.276—-52.44 ± 20.855-63.14 ± 36.841
Week 32-98.31 ± NA-71.63 ± 30.130—-71.33 ± 26.153-94.97 ± 6.004-61.76 ± 38.208—-53.49 ± 21.065-53.15 ± 40.480
Week 48—-86.97 ± 17.571—————-94.15 ± NA-60.37 ± NA

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Week 59. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Placebo0/3 (0%)1/3 (33.3%)0/3 (0%)
Placebo/GSK1070806 Dose Level 40/13 (0%)0/13 (0%)11/13 (84.6%)
GSK1070806 Dose Level 1/GSK1070806 Dose Level 10/2 (0%)0/2 (0%)1/2 (50%)
GSK1070806 Dose Level 1/GSK1070806 Dose Level 40/11 (0%)1/11 (9.1%)6/11 (54.5%)
GSK1070806 Dose Level 2/GSK1070806 Dose Level 20/8 (0%)0/8 (0%)4/8 (50%)
GSK1070806 Dose Level 2/GSK1070806 Dose Level 40/6 (0%)0/6 (0%)5/6 (83.3%)
GSK1070806 Dose Level 3/GSK1070806 Dose Level 30/1 (0%)0/1 (0%)1/1 (100%)
GSK1070806 Dose Level 3/GSK1070806 Dose Level 40/8 (0%)0/8 (0%)5/8 (62.5%)
GSK1070806 Dose Level 4/GSK1070806 Dose Level 40/27 (0%)0/27 (0%)10/27 (37%)
Most frequent serious events
Most frequent serious events
EventPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
Necrotising soft tissue infectionInfections and infestations1/30/130/20/110/80/60/10/80/27
Diabetic ketoacidosisMetabolism and nutrition disorders1/30/130/20/110/80/60/10/80/27
CellulitisInfections and infestations0/30/130/21/110/80/60/10/80/27
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlacebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4
AnaemiaBlood and lymphatic system disorders0/30/130/20/110/80/61/10/81/27
InfluenzaInfections and infestations0/30/130/21/110/82/61/11/80/27
Blood fibrinogen decreasedInvestigations0/30/130/20/110/80/61/10/80/27
Urticaria cholinergicSkin and subcutaneous tissue disorders0/30/130/20/110/80/61/10/80/27
Ligament sprainInjury, poisoning and procedural complications0/30/131/20/110/80/60/10/81/27
NasopharyngitisInfections and infestations0/32/130/24/111/80/60/12/82/27
EosinophiliaBlood and lymphatic system disorders0/30/130/20/110/80/60/12/80/27
Dermatitis atopicSkin and subcutaneous tissue disorders0/30/130/22/110/80/60/11/80/27
FolliculitisInfections and infestations0/31/130/20/110/81/60/10/80/27
Herpes zosterInfections and infestations0/30/130/20/110/81/60/10/81/27

Baseline characteristics

Baseline characteristics were reported for Enrolled Analysis Set which consisted of all participants who signed the informed consent form and entered the study. Participants are included in the treatment group in which they entered the long-term extension study (Study 220723 \[NCT06447506\]).

Age, Customized
Age, Customized(Participants)Placebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4Total
18 to 64 years11331095182676
>=65 to 84 years2000000013
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Placebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4Total
Female180520011229
Male253575071549
Not Reported0000001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/PlaceboPlacebo/GSK1070806 Dose Level 4GSK1070806 Dose Level 1/GSK1070806 Dose Level 1GSK1070806 Dose Level 1/GSK1070806 Dose Level 4GSK1070806 Dose Level 2/GSK1070806 Dose Level 2GSK1070806 Dose Level 2/GSK1070806 Dose Level 4GSK1070806 Dose Level 3/GSK1070806 Dose Level 3GSK1070806 Dose Level 3/GSK1070806 Dose Level 4GSK1070806 Dose Level 4/GSK1070806 Dose Level 4Total
AMERICAN INDIAN OR ALASKA NATIVE0001000001
ASIAN270542131135
BLACK OR AFRICAN AMERICAN0110000204
WHITE141252031331
MIXED RACE0101000013
NOT REPORTED0011010025
08

Study locations

51 sites
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Pompano Beach, Florida 33334, United States
  • GSK Investigational Site
    Fayetteville, Georgia 30214, United States
  • GSK Investigational Site
    New York, New York 10075, United States
  • GSK Investigational Site
    Dublin, Ohio 43016, United States
  • GSK Investigational Site
    Santa Monica, Texas 90404, United States
  • GSK Investigational Site
    Buenos Aires, C1055AAO, Argentina
  • GSK Investigational Site
    Buenos Aires, C1181ACH, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABI, Argentina
  • GSK Investigational Site
    Córdoba, X5000AAW, Argentina
  • GSK Investigational Site
    Rosario, S2002, Argentina
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Sofia, 1510, Bulgaria
  • GSK Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • GSK Investigational Site
    London, Ontario N6H 5L5, Canada
  • GSK Investigational Site
    Markham, Ontario L3P1X2, Canada
  • GSK Investigational Site
    Chongqing, 400016, China
  • GSK Investigational Site
    Hangzhou, 310000, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, China
  • GSK Investigational Site
    Prague, 10034, Czechia
  • GSK Investigational Site
    Prague, Czechia
  • GSK Investigational Site
    La Rochelle, 17019, France
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Münster, 48149, Germany
  • GSK Investigational Site
    Athens, Greece
  • GSK Investigational Site
    Chiba, 272-0033, Japan
  • GSK Investigational Site
    Fukuoka, 807-8556, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Gunma, 370-0829, Japan
  • GSK Investigational Site
    Hokkaido, 060-0033, Japan
  • GSK Investigational Site
    Hokkaido, 080-0013, Japan
  • GSK Investigational Site
    Kanagawa, 211-0063, Japan
  • GSK Investigational Site
    Osaka, 583-8588, Japan
  • GSK Investigational Site
    Osaka, 593-8324, Japan
  • GSK Investigational Site
    Saitama, 343-8555, Japan
  • GSK Investigational Site
    Chihuahua City, 31000, Mexico
  • GSK Investigational Site
    Durango, 34000, Mexico
  • GSK Investigational Site
    Guadalajara, 44628, Mexico
  • GSK Investigational Site
    Panama City, 7099, Panama
  • GSK Investigational Site
    Elblag, 82-300, Poland
  • GSK Investigational Site
    Katowice, 40-600, Poland
  • GSK Investigational Site
    Szczecin, 70-332, Poland
  • GSK Investigational Site
    Ansan, 15355, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 04763, South Korea
  • GSK Investigational Site
    Seoul, 100 799, South Korea
  • GSK Investigational Site
    Seoul, 150-950, South Korea
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Granada, 18016, Spain
  • GSK Investigational Site
    Vigo, 36206, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jul 2025, 13 months.

Results were first posted in Jun 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
Jun 5, 2024
Primary completionActual
Jul 29, 2025
CompletionActual
Jul 29, 2025
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06447506
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Jun 5, 2024
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1070806

Start the discussion